Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2019-11-12 Earnings Release
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text specifically mentions the announcement of results of operations for the three and nine months ended September 30, 2019, and a press release is furnished as an exhibit. It also mentions an investor conference call to discuss the third quarter financial results and business outlook. The document itself is short (2774 characters) and primarily serves to announce the earnings release and the upcoming call, rather than containing detailed financial statements or analysis. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2019-11-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions the issuance of a press release about clinical trial data, filed as an exhibit. The document is short (2629 characters) and primarily serves as an announcement of an event and a press release, not a detailed financial report or earnings release. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-10-28 English
FORM 4
Director's Dealing
2019-09-18 English
FORM 4
Director's Dealing
2019-09-18 English
FORM 4
Director's Dealing
2019-09-18 English
FORM 4
Director's Dealing
2019-09-18 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.